Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 15/20 | 0.38 |
| ▸ | DRD4 | P21917 | 15/20 | 0.38 |
| ▸ | DRD3 | P35462 | 15/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24394153 | 0.87 | ALDH1A1 (0.37) | HSD11B1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL24397786 | 0.87 | APP (0.38) | — | |
| SCHEMBL24397743 | 0.83 | DRD2 (0.39) | HSD11B1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL26941571 | 0.83 | OPRM1 (0.36) | HSD11B1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL24398057 | 0.83 | MAPK1 (0.36) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL24397842 | 0.82 | OPRM1 (0.32) | — | |
| SCHEMBL24397784 | 0.82 | OPRM1 (0.32) | — | |
| SCHEMBL24394104 | 0.82 | THRB (0.37) | — | |
| SCHEMBL26958140 | 0.81 | MAPT (0.38) | HSD11B1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL24397870 | 0.81 | SLC6A4 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| WO-2022090724-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | HSD11B1 146/4885DRD2 2698/4885DRD4 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.